The study analysed that the PTSD pipeline comprises of 23
drug candidates in different stages of development. PTSD is a neurological
disorder that develops in people who have experienced a scary or a dangerous
event. PTSD can occur in a person at any age. According to the National Center
of PTSD, around seven to eight out of 100 individuals experience PTSD at some
point in their lives. Most of the people recover from traumatic situation
naturally, but those who continue to experience problems are diagnosed with
PTSD. People with PTSD are used to feel frightened even when they are not in a
dangerous situation. PTSD generally occurs more often in women than men.
Various collaboration between educational institutes, associations, and pharma
companies are driving the therapeutic pipeline of PTSD.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis
Many patents have been received during the development of drug
candidates for the treatment of PTSD. In May 2017, Tonix reported the issuance
of patent 9 636 408 by the United States Patent and Trademark Office titled
“Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline
Hydrochloride,” covering the composition and manufacture of its proprietary
sublingual formulation of very low dose cyclobenzaprine.
Significant growth in the therapeutic pipeline of PTSD is attributed to
increasing collaboration between educational institutes, associations and
pharma companies. Funds from the non-profit organizations have also been
supporting the pipeline growth of PTSD therapeutics.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis/report-sample
Some of the key players developing drugs for the treatment of PTSD
include India Globalization Capital, Inc., Therapade Technologies LLC, Axim
Biotechnologies, Inc. and others.
No comments:
Post a Comment